Form 8-K - Current report:
SEC Accession No. 0000950170-24-124636
Filing Date
2024-11-12
Accepted
2024-11-12 08:11:32
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001991792-20241112.htm   iXBRL 8-K 46281
2 EX-99.1 ck0001991792-ex99_1.htm EX-99.1 25785
3 GRAPHIC img89521117_0.jpg GRAPHIC 12203
  Complete submission text file 0000950170-24-124636.txt   215713

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20241112.xsd EX-101.SCH 26974
15 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20241112_htm.xml XML 5113
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 241443613
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)